DexCom(DXCM) - 2024 Q4 - Annual Results

Financial Results and Guidance - DexCom will report preliminary, unaudited financial results for Q4 2024 and fiscal year 2024, along with initial financial outlook for fiscal year 2025[3] - The preliminary unaudited financial results for Q4 and fiscal year 2024 are subject to finalization in DexCom's Annual Report on Form 10-K[9] - DexCom's forward-looking statements include preliminary unaudited revenue for Q4 and full fiscal year 2024, including growth rates[9] - DexCom provided total revenue guidance for fiscal year 2025[9] - DexCom provided Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal years 2024 and 2025, including expected growth rates[9] Forward-Looking Statements and Risks - DexCom's forward-looking statements also include potential strategic and business opportunities[9] - The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from current expectations[9] - DexCom assumes no obligation to update forward-looking statements after the date of the report unless required by law[9] Regulatory and Filing Information - The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934[10] - The information in the report and exhibit is not incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act unless expressly set forth[10]